Inhibitors of HDAC (HDACi) can be utilized for treating refractory cutaneous T-cell lymphoma, indicating the possibility of helping COAD patients by targeting HDAC family members11. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.